Skip to main content
SpringerLink
Log in

Valrubicin

  • Adis New Drug Profile
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

  • ▲ Valrubicin (AD-32) is an N-trifluoroacetyl, 14-valerate derivative of the anthracycline doxorubicin. It has antineoplastic activity which probably results from interference with nucleic acid metabolism by the drug.

  • ▲ Valrubicin entered individual cells more rapidly than doxorubicin in vitro. When valrubicin was administered intravesically to patients with bladder cancer, cytotoxic concentrations of the drug penetrated the superficial muscle layer of the bladder.

  • ▲ Complete response rates were 18 and 29% in patients with carcinoma in situ of the bladder which was refractory to intravesical BCG in 2 non-comparative trials of prophylactic intravesical valrubicin. In patients with recurrent superficial papillary tumours, the complete response rate was 46%.

  • ▲ Adverse events were generally transient in patients who received intravesical valrubicin. Bladder irritation occurred in 88% of patients. Systemic absorption of intravesically administered valrubicin was minimal. Accordingly, systemic adverse events generally occurred in ≤5% of patients.

  • ▲ Valrubicin was less toxic to chick embryos and haematopoietic stem cells in vitro and produced a lower incidence of cardiotoxicity in rabbits, compared with doxorubicin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Witjes JA. Current recommendations for the management of bladder cancer: drug therapy. Drugs 1997; 53: 404–14

    Article  PubMed  CAS  Google Scholar 

  2. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol 1995; 153: 564–72

    Article  PubMed  CAS  Google Scholar 

  3. van Gils-Gielen RJM, Debruyne FMJ, Witjes WPJ, et al. Risk factors in carcinoma in situ of the urinary bladder. Urology 1995; 45 (4): 581–6

    Article  PubMed  Google Scholar 

  4. Gohji K, Nomi M, Okamoto M, et al. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 1999; 53: 308–13

    Article  PubMed  CAS  Google Scholar 

  5. Scher HI, Shipley WU, Herr HW. Cancer of the bladder. In: DeVita VTJ, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997: 1300–22

    Google Scholar 

  6. Cummings KB. Uroepithelial tumors. In: Moosa AR, Schimpff SC, Robson MC, editors. Comprehensive textbook of oncology. 2nd ed. Baltimore: Williams and Wilkens, 1991: 1067–87

    Google Scholar 

  7. Nseyo UO, Lamm DL. Therapy of superficial bladder cancer. Semin Oncol 1996; 23: 598–604

    PubMed  CAS  Google Scholar 

  8. Nseyo UO, Lamm DL. Immunotherapy of bladder cancer. Semin Surg Oncol 1997; 13: 342–9

    Article  PubMed  CAS  Google Scholar 

  9. Kurth KH. Diagnosis and treatment of superficial transitional cell carcinoma of the bladder: facts and perspectives. Eur Urol 1997; 31 Suppl. 1: 10–9

    PubMed  Google Scholar 

  10. Copien DE, Marcus MD, Myers JA, et al. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical Bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol 1990 Sep; 144: 652–7

    Google Scholar 

  11. Chow K-C, Macdonald TL, Ross WE. DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition. Mol Pharmacol 1988; 34 (4): 467–73

    PubMed  CAS  Google Scholar 

  12. Silber R, Liu LF, Israel M, et al. Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr 1987; 4: 111–5

    PubMed  Google Scholar 

  13. Blum RH, Garnick MB, Israel M, et al. Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32. Recent Results Cancer Res 1981; 76: 7–15

    PubMed  CAS  Google Scholar 

  14. Kanter PM, Schwartz HS. Effects of N-trifluoroacetyl-adriamycin-14-valerate and related agents on DNA strand damage and thymidine incorporation in CCRF-CEM cells. Cancer Res 1979; 39 (2 Pt 1): 448–51

    PubMed  CAS  Google Scholar 

  15. Niell HB, Hunter RF, Herrod HG, et al. Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines. Cancer Chemother Pharmacol 1987; 19: 47–52

    Article  PubMed  CAS  Google Scholar 

  16. Israel M, Modest EJ, Frei E III. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res 1975; 35: 1365–8

    PubMed  CAS  Google Scholar 

  17. Vecchi A, Cairo M, Mantovani A, et al. Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate. Cancer Treat Rep 1978; 62: 111–7

    PubMed  CAS  Google Scholar 

  18. Henderson IC, Billingham M, Israel M, et al. Comparative cardiotoxicity studies with adriamycin (ADR) and AD 32 in rabbits [abstract no. 632]. Proceedings of the American Association of Cancer Research 1978; 19: 158

    Google Scholar 

  19. Zirvi KA, Gilani SH, Hill GJ. Embryotoxic effects of doxorubicin and N-trifluoroacetyladriamycin-14-valerate (AD-32). Teratology 1985; 31: 247–52

    Article  PubMed  CAS  Google Scholar 

  20. Medeva Pharmaceuticals I. Valstar™ (valrubicin) sterile solution for intravesical instillation — prescribing information. London: Medeva Pharmaceuticals I, 1998

    Google Scholar 

  21. Krishan A, Israel M, Modest EJ, et al. Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate. Cancer Res 1976; 36: 2108–9

    PubMed  CAS  Google Scholar 

  22. Burke TG, Israel M, Seshadri R, et al. A fluorescence study examining how 14-valerate side chain substitution modulates anthracycline binding to small unilamellar phospholipid vesicles. Biochim Biophys Acta 1989; 982 (1): 123–30

    Article  PubMed  CAS  Google Scholar 

  23. Sweatman TW, Payne C, Patterson L, et al. Penetration of intravesical N-trifluoroacetyladriamycin-14-valerate into human urinary bladder tissue; a clinical pharmacology study [abstract]. 87th Annual Meeting of the American Association for Cancer Research (AACR): 1996 Apr 20–24; Washington, DC: 182

  24. Sweatman TW, Payne C, Israel M, et al. Clinical pharmacology of intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32) [abstract]. Proc Am Soc Clin Oncol 1993; 12: 162

    Google Scholar 

  25. Israel M, Karkowsky AM, Pegg WJ. Pharmacologic studies with radiolabeled N-trifluoroacetyladriamycin-14-valerate (AD 32): comparison of total anthracycline fluorescence and radioactivity in mouse serum and urine. Cancer Chemother Pharmacol 1980; 4: 79–82

    Article  PubMed  CAS  Google Scholar 

  26. Greenberg RE, Bahnson RR, Wood D, et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 1997; 49: 471–5

    Article  PubMed  CAS  Google Scholar 

  27. Newling DWW, Robinson MRG, Whelan P, et al. AD32 — A new doxirubicin derivative in superficial bladder cancer — interim results of the European study A9304 [abstract]. Br J Urol 1997; 80 Suppl. 2: 36

    Google Scholar 

  28. Bahnson R, Brosman S, Greenberg R, et al. Multicenter efficacy and safety study of intravesical AD 32 (Valrubicin) in the treatment of patients with refractory bladder carcinoma in situ [abstract]. J Urol 1998; 159 Suppl.: 145

    Article  Google Scholar 

  29. Bahnson R, Brosman S, Dalkin B, et al. Effectiveness of valrubicin in patients with BCG-refractory carcinoma in situ of the bladder [abstract no. 660]. J Urol 1999; 161 (4) Suppl.: 171

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bay 65901, Mairangi Bay, Auckland 10, New Zealand

    Susan V. Onrust & Harriet M. Lamb

Authors
  1. Susan V. Onrust
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harriet M. Lamb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan V. Onrust.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Onrust, S.V., Lamb, H.M. Valrubicin. Drugs & Aging 15, 69–75 (1999). https://doi.org/10.2165/00002512-199915010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199915010-00006

Keywords

Search

Navigation